These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2419435)

  • 21. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment.
    Pachner AR
    Yale J Biol Med; 1987; 60(2):169-77. PubMed ID: 3495075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
    Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
    J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular aspects of experimental autoimmune myasthenia gravis.
    Fuchs S; Bartfeld D; Mochly-Rosen D; Schmidt-Hopfeld I; Tarrab-Hazdai R
    Prog Clin Biol Res; 1981; 63():405-17. PubMed ID: 7031685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens.
    Swain SL; Dialynas DP; Fitch FW; English M
    J Immunol; 1984 Mar; 132(3):1118-23. PubMed ID: 6198377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.
    Okumura S; McIntosh K; Drachman DB
    Ann Neurol; 1994 Nov; 36(5):704-13. PubMed ID: 7979216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
    Fujii Y; Lindstrom J
    J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.
    Killen JA; Lindstrom JM
    J Immunol; 1984 Nov; 133(5):2549-53. PubMed ID: 6332854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenetics of experimental autoimmune myasthenia gravis.
    Christadoss P
    Crit Rev Immunol; 1989; 9(4):247-78. PubMed ID: 2679661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
    Atassi MZ; Oshima M
    Crit Rev Immunol; 1997; 17(5-6):481-95. PubMed ID: 9419435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular immune response to acetylcholine receptors in murine experimental autoimmune myasthenia gravis: inhibition with monoclonal anti-I-A antibodies.
    Christadoss P; Lindstrom J; Talal N
    Cell Immunol; 1983 Oct; 81(1):1-8. PubMed ID: 6577968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis.
    Gomez CM; Richman DP
    J Immunol; 1985 Jul; 135(1):234-41. PubMed ID: 3873489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo actions of acetylcholine receptor educated suppressor T cell lines in murine experimental autoimmune myasthenia gravis.
    Pachner AR; Kantor FS
    Clin Exp Immunol; 1984 Jun; 56(3):659-68. PubMed ID: 6235071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
    Zhang GX; Xiao BG; Bai XF; van der Meide PH; Orn A; Link H
    J Immunol; 1999 Apr; 162(7):3775-81. PubMed ID: 10201893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C5 gene influences the development of murine myasthenia gravis.
    Christadoss P
    J Immunol; 1988 Apr; 140(8):2589-92. PubMed ID: 3356901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of antigen-specific therapies for autoimmune disease.
    Steinman L
    Mol Biol Med; 1990 Aug; 7(4):333-9. PubMed ID: 2233245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes.
    Nicolle MW; Nag B; Sharma SD; Willcox N; Vincent A; Ferguson DJ; Newsom-Davis J
    J Clin Invest; 1994 Apr; 93(4):1361-9. PubMed ID: 7512979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells.
    Shi FD; Li H; Wang H; Bai X; van der Meide PH; Link H; Ljunggren HG
    J Immunol; 1999 May; 162(10):5757-63. PubMed ID: 10229808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis.
    Wang HB; Shi FD; Li H; Chambers BJ; Link H; Ljunggren HG
    J Immunol; 2001 May; 166(10):6430-6. PubMed ID: 11342669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined short-term immunotherapy for experimental autoimmune myasthenia gravis.
    Pestronk A; Drachman DB; Teoh R; Adams RN
    Ann Neurol; 1983 Aug; 14(2):235-41. PubMed ID: 6354071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.